US Stock MarketDetailed Quotes
GMAB Genmab
- 22.560
- +0.240+1.08%
Close Nov 1 16:00 ET
- 22.560
- 0.0000.00%
Post 20:02 ET
14.33BMarket Cap18.31P/E (TTM)
22.630High22.525Low1.11MVolume22.605Open22.320Pre Close25.13MTurnover0.18%Turnover Ratio23.43P/E (Static)635.06MShares32.89052wk High3.17P/B14.17BFloat Cap22.22052wk Low--Dividend TTM628.29MShs Float49.070Historical High--Div YieldTTM0.47%Amplitude16.240Historical Low22.573Avg Price1Lot Size
About Genmab Company
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.
Company Profile
SymbolGMAB
Company NameGenmab
Listing DateJul 18, 2019
Issue Price17.75
Founded1998
CEODr. Jan G. J. van de Winkel, PhD
MarketNASDAQ
Employees2204
Securities TypeDR
ADS Ratio10.0 : 1.0
Fiscal Year Ends12-31
AddressCarl Jacobsens Vej 30,Valby
CityCopenhagen
ProvinceCentral Denmark
CountryDenmark
Zip Code2500
Phone45-70-20-27-28
Websitehttp://www.genmab.com
Company Executives
- Name
- Position
- Salary
- Dr. Jan G. J. van de Winkel, PhD
- President and Chief Executive Officer
- 44.30M
- Christopher Cozic
- Executive Vice President and Chief People Officer
- 13.20M
- Dr. Tahamtan Ahmadi, PhD
- Executive Vice President, Chief Medical Officer and Head of Experimental Medicines
- 19.80M
- Anthony Pagano
- Executive Vice President and Chief Financial Officer
- 19.60M
- Birgitte Stephensen
- Executive Vice President and Chief Legal Officer
- 10.10M
- Anthony Mancini
- Executive Vice President and Chief Operating Officer
- 21.80M
- Dr. Martine J. van Vugt, PhD
- Executive Vice President and Chief Strategy Officer
- 8.90M
- Dr. Judith Klimovsky
- Executive Vice President and Chief Development Officer
- 21.70M
- Dr. Mijke Zachariasse
- Director, Vice President and Head of Antibody Research Materials
- 1.10M
- Deirdre P. Connelly
- Chairman of the Board
- 2.80M
- Pernille Erenbjerg
- Deputy Chairman of the Board
- 2.10M
- Martin Schultz
- Director, Senior Director and Head of Development Business Partnership and Strategy
- 800.00K
- Anders Gersel Pedersen, M.D.,PhD
- Director
- 1.70M
- Takahiro Hamatani
- Director and Senior Director, Finance Japan
- 800.00K
- Elizabeth G. O’Farrell
- Independent Director
- 1.90M
- Rolf Karl-Heinz Hoffmann
- Independent Director
- 1.50M
- Dr. Paolo Paoletti, M.D.
- Independent Director
- 1.50M
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data